CytomX Therapeutics (CTMX) Debt to Equity (2014)

CytomX Therapeutics (CTMX) reported Debt to Equity of -$0.04 for Q4 2014.

CytomX Therapeutics (CTMX) Debt to Equity (2014) Analysis & Trends

CytomX Therapeutics has reported Debt to Equity for 1 years, with the latest figure at -$0.04 in Q4 2014.

  • For the quarter ending Q4 2014, Debt to Equity changed N/A year-over-year to -$0.04; the trailing twelve-month figure through Dec 2014 stood at -$0.04 (changed N/A YoY), and the FY2014 full-year result was -$0.04, changed N/A from the prior year.
  • Debt to Equity for Q4 2014 stood at -$0.04.
  • The five-year high for Debt to Equity was -$0.04 in Q4 2014, with the low at -$0.04 in Q4 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.32
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 CytomX Therapeutics 520.30 Mn 173.59 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2014 -0.04